OUR PRECISION CANCER IMMUNOTHERAPIES ARE BASED ON
ANCER™ 
A SUPERIOR NEOANTIGEN PREDICTION PLATFORM
POWERED BY MACHINE LEARNING BASED ALGORITHMS 

 

Next-generation sequencing has opened the door to precision cancer immunotherapies targeting mutations solely expressed by tumor cells.

Ancer™ prioritizes both CD8 and CD4 T cell neoepitopes and removes "Self-Like" inhibitory and cross reactive neoepitopes.

Ancer™ enables the rapid, in silico, discovery of highly immunogenic neoantigens for precision cancer immunotherapies.

Learn more about Ancer™ here.

© Copyright Epivax Oncology 2020